+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Heart Failure Therapeutics Market - Global Forecast 2026-2032- Product Image
Heart Failure Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Heart Failure Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532841
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Heart Failure Therapeutics Market is projected to reach USD 31.69 Billion in 2026. It is expected to continue growing at a CAGR of 10.94%, reaching USD 60.23 Billion by 2032.

Heart failure therapeutics remain central to cardiovascular care because heart failure affects more than 64 million people worldwide, while cardiovascular diseases cause an estimated 17.9 million deaths each year, according to the World Health Organization. The heart failure treatment landscape is shifting from episodic symptom control toward guideline-directed medical therapy that lowers mortality, reduces hospitalization, improves functional status, and slows disease progression across reduced, mildly reduced, and preserved ejection fraction.

Demand for evidence-based heart failure drugs is reinforced by aging populations, diabetes, obesity, hypertension, chronic kidney disease, and improved survival after myocardial infarction. Clinicians are increasingly using angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, diuretics, iron repletion, and device-enabled care in integrated pathways designed to improve outcomes and support long-term disease management.

Transformative Shifts in the Heart Failure Landscape

The heart failure therapeutics landscape is being reshaped by the rapid adoption of four-pillar treatment for heart failure with reduced ejection fraction, wider use of SGLT2 inhibitors across ejection-fraction categories, and earlier initiation of combination therapy after diagnosis or hospital discharge. Major guidelines from the AHA, ACC, HFSA, and ESC emphasize faster optimization of evidence-based medicines rather than slow sequential escalation, reflecting clinical trial evidence that timely treatment reduces cardiovascular death and heart failure hospitalization.

Commercial strategy is also changing. Payers increasingly evaluate heart failure therapies by their ability to reduce hospital admissions, improve quality of life, support outpatient management, and lower avoidable acute-care use. At the same time, patent expirations, generic availability, fixed-dose combinations, remote patient monitoring, and multidisciplinary care models are changing access, pricing, adherence, and differentiation across the heart failure drug market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler in heart failure therapeutics rather than a standalone treatment. Validated AI tools are being applied to electrocardiogram interpretation, echocardiography workflows, risk stratification, patient identification, medication adherence support, and prediction of clinical decompensation using electronic health records, imaging, laboratory results, wearable devices, and remote monitoring data.

The cumulative impact is strongest where AI improves earlier diagnosis, therapy titration, clinical trial recruitment, population health management, and pharmacovigilance. However, adoption depends on transparent validation, demographic fairness, cybersecurity, clinician oversight, and regulatory alignment. For drug developers and healthcare decision-makers, AI-enabled real-world evidence can strengthen market access dossiers, identify underdiagnosed patients, and support selection of patients most likely to benefit from specific heart failure therapies.

Key Regional Insights Across Heart Failure Therapeutics

Asia-Pacific is a highly dynamic heart failure therapeutics region due to large aging populations, rising diabetes prevalence, urbanization, and expanding cardiology infrastructure across China, India, Japan, Australia, and South Korea. North America remains a leading innovation and adoption hub, supported by AHA/ACC/HFSA guideline implementation, specialist heart failure programs, clinical trial density, advanced diagnostics, and comparatively strong reimbursement for branded therapies, outpatient care models, and digital health integration.

Latin America shows increasing demand for heart failure treatment but faces uneven access to advanced medicines, diagnostics, and specialist services, with Brazil and Mexico acting as key regional anchors. Europe benefits from ESC-led standardization, national health technology assessment systems, broad use of evidence-based therapy, and structured pharmacovigilance, although cost-effectiveness scrutiny is significant. The Middle East is expanding cardiovascular investment as diabetes, hypertension, and obesity burden rises, while Africa remains underpenetrated, with affordability, diagnosis rates, workforce capacity, and supply continuity shaping therapeutic uptake.

Key Group Insights for Strategic Market Positioning

ASEAN markets are gaining relevance as hospital networks expand and governments strengthen noncommunicable disease programs, though access to newer heart failure medicines varies by reimbursement, public procurement, and urban-rural capacity. The GCC is strategically important because high rates of diabetes, hypertension, obesity, and chronic kidney disease create sustained demand for cardiometabolic and heart failure care, supported by healthcare modernization programs, specialty centers, and investment in digital health infrastructure.

The European Union provides regulatory scale, pharmacovigilance infrastructure, and health technology assessment-driven pricing discipline, making clinical value and budget impact central to access. BRICS countries combine large patient pools with rising domestic manufacturing, expanding insurance coverage, and cost-sensitive procurement, making affordability, local evidence, and supply reliability essential. G7 markets lead in clinical innovation, premium therapy adoption, and real-world evidence generation. NATO members, while not a healthcare bloc, overlap with major high-income markets where supply-chain resilience, essential medicines security, and health-system readiness are increasingly strategic priorities.

Key Country Insights in Major Heart Failure Markets

The United States is the most commercially influential heart failure therapeutics market, supported by high disease burden, advanced specialty care, broad clinical trial participation, and rapid incorporation of guideline-directed medical therapy; Canada follows similar clinical standards with stronger centralized cost-effectiveness review and provincial reimbursement influence. Mexico and Brazil are important Latin American markets where public access, private insurance penetration, local procurement, and specialist availability determine uptake of advanced heart failure medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature cardiology systems with pricing oversight, national reimbursement rules, and guideline-based care pathways, while Russia presents a large patient base with access, procurement, and geopolitical constraints. China and India drive Asia-Pacific patient volume, supported by expanding diagnosis, domestic manufacturing, hospital capacity, and policy attention to chronic disease management. Japan, Australia, and South Korea are advanced markets with strong regulatory standards, aging populations, high-quality cardiovascular care, and growing interest in integrated drug-device-digital heart failure management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and programs that demonstrably reduce hospitalization, cardiovascular mortality, symptom burden, and total cost of care. Portfolio strategies should align with guideline-directed medical therapy, support rapid titration, and address common comorbidities such as chronic kidney disease, diabetes, iron deficiency, hypertension, atrial fibrillation, and obesity.

Manufacturers should expand real-world evidence, pursue inclusive clinical trials, strengthen payer-ready economic models, and invest in patient support that improves treatment persistence and adherence. Regional strategies must balance premium innovation with affordability through tiered pricing, local partnerships, supply security, physician education, and care pathway support for primary care and cardiology teams. AI-enabled identification, remote monitoring integration, decentralized follow-up, and outcomes-based contracting can further improve differentiation in heart failure therapeutics.

Research Methodology

The research methodology is built on secondary research from verified public and scientific sources, including global health agencies, cardiology guidelines, regulatory labels, peer-reviewed clinical trials, health technology assessment frameworks, epidemiology databases, and disease burden publications. Priority was given to evidence from the World Health Organization, AHA/ACC/HFSA, ESC, national regulatory authorities, and landmark randomized heart failure trials evaluating mortality, hospitalization, safety, and quality-of-life outcomes.

Insights were triangulated across disease burden, treatment standards, regulatory status, reimbursement dynamics, clinical adoption, access barriers, comorbidity patterns, and regional healthcare capacity. The analysis avoids unsupported market-size claims and focuses on evidence-backed therapeutic, geographic, and strategic signals relevant to heart failure drug developers, investors, payers, providers, and healthcare decision-makers.

Conclusion

Heart failure therapeutics are entering a more outcomes-driven phase defined by earlier diagnosis, faster initiation of combination therapy, broader SGLT2 inhibitor use, stronger comorbidity management, and deeper integration of digital and AI-enabled care. The competitive landscape rewards therapies that improve survival, reduce hospitalization, simplify care pathways, enhance adherence, and prove value in real-world heart failure populations.

Growth opportunities are strongest where clinical innovation is paired with access strategy and implementation support. Organizations that combine robust evidence, regional affordability, payer engagement, supply reliability, and technology-enabled patient management will be best positioned to meet rising demand across mature and emerging heart failure therapeutics markets.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Heart Failure Therapeutics Market, by Drug Class
7.1. Introduction
7.2. ACE Inhibitors
7.3. Angiotensin II Receptor Blockers
7.4. Beta Blockers
7.5. Diuretics
7.6. Mineralocorticoid Receptor Antagonists
7.7. SGLT2 Inhibitors
8. Heart Failure Therapeutics Market, by Heart Failure Type
8.1. Introduction
8.2. Preserved Ejection Fraction
8.3. Reduced Ejection Fraction
8.4. Heart Failure with Mildly Reduced EF
9. Heart Failure Therapeutics Market, by Mode Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Heart Failure Therapeutics Market, by Mechanism of Action
10.1. Introduction
10.2. Neurohormonal Modulation
10.3. Vasodilation
10.4. Positive Inotropy
10.5. Metabolic Modulation
11. Heart Failure Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Heart Failure Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.3. Online
13. Heart Failure Therapeutics Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Heart Failure Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Heart Failure Therapeutics Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. United Kingdom
15.5. India
15.6. Canada
15.7. France
15.8. Mexico
15.9. Brazil
15.10. Australia
15.11. Japan
15.12. South Korea
15.13. Italy
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Abiomed, Inc.
17.3. Amgen Inc.
17.4. AstraZeneca PLC
17.5. Bayer AG
17.6. BioCardia, Inc.
17.7. Boehringer Ingelheim International GmbH
17.8. Boston Scientific Corporation
17.9. Bristol-Myers Squibb Company
17.10. CVRx, Inc.
17.11. Cytokinetics, Inc.
17.12. Edwards Lifesciences Corporation
17.13. Eli Lilly and Company
17.14. GlaxoSmithKline plc
17.15. Hikma Pharmaceuticals PLC
17.16. Johnson & Johnson Services, Inc.
17.17. Les Laboratoires Servier
17.18. Medtronic plc
17.19. Merck & Co., Inc.
17.20. Novartis AG
17.21. Orion Corporation
17.22. Pfizer Inc.
17.23. PhaseBio Pharmaceuticals, Inc.
17.24. Renova Therapeutics, Inc.
17.25. Sanofi S.A.
17.26. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ACE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ACE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ACE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DIURETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DIURETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DIURETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL VASODILATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL VASODILATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL VASODILATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL METABOLIC MODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL METABOLIC MODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL METABOLIC MODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 100. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 102. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 105. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 106. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 116. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 118. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 119. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 121. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 127. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 128. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 130. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 133. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 135. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 136. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 137. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 138. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 149. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 151. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 152. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 153. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 154. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 157. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 159. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 160. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 161. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 162. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 165. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 167. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 168. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 170. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 174. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 175. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 176. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 182. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 183. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 184. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 185. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 186. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 187. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 190. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 191. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 192. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 193. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 195. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 198. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 206. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 209. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 211. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 214. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 215. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 216. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 217. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 219. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 220. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 222. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 224. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 225. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 226. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 227. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 230. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 231. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 232. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 233. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 235. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 240. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 241. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 246. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 248. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 249. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 250. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 251. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 254. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 256. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 257. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 259. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 264. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 265. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 267. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 270. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 272. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 273. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 275. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 286. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 288. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2017-2032 (USD MILLION)
TABLE 289. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 291. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2017-2032 (USD MILLION)
TABLE 294. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 295. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Abiomed, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCardia, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CVRx, Inc.
  • Cytokinetics, Inc.
  • Edwards Lifesciences Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Les Laboratoires Servier
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Renova Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 31.69 Billion
Forecasted Market Value ( USD ) by 2032 $ 60.23 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Dilated Cardiomyopathy Therapeutics Market - Global Forecast 2026-2032 - Product Image

Dilated Cardiomyopathy Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Nonsteroidal MRAs Market - Global Forecast 2026-2032 - Product Image

Nonsteroidal MRAs Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Heart Failure Drugs Market by Type of Heart Failure, Type of Therapy, Type of Molecule, Route of Administration, Geographical Regions, Sales Forecast - Trends and Forecast Till 2035 - Product Image

Heart Failure Drugs Market by Type of Heart Failure, Type of Therapy, Type of Molecule, Route of Administration, Geographical Regions, Sales Forecast - Trends and Forecast Till 2035

  • Report
  • 177 Pages
  • Global
From
Cardiovascular Clinical Trials - Global Strategic Business Report - Product Image

Cardiovascular Clinical Trials - Global Strategic Business Report

  • Report
  • 393 Pages
  • Global
From

About the Heart Failure Drug Market

The Heart Failure Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat a variety of heart-related conditions. Heart Failure Drugs are used to treat heart failure, a condition in which the heart is unable to pump enough blood to meet the body's needs. These drugs can help reduce symptoms, improve quality of life, and reduce the risk of death. Commonly used Heart Failure Drugs include ACE inhibitors, beta blockers, diuretics, and angiotensin receptor blockers. These drugs work by reducing the workload on the heart, improving blood flow, and reducing fluid buildup in the body. Some companies in the Heart Failure Drug market include Pfizer, Novartis, Merck, Sanofi, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.